Welcome to our dedicated page for eXoZymes news (Ticker: EXOZ), a resource for investors and traders seeking the latest updates and insights on eXoZymes stock.
eXoZymes Inc. develops AI-enhanced enzymes and a cell-free biomanufacturing platform for producing high-value natural products from abundant feedstock. Company news centers on exozymes, enzyme cascades operating outside living cells, and the use of the platform in nutraceuticals, novel medicines, active pharmaceutical ingredients, biofuels, food flavors, cosmetics, and valuable chemicals.
Recurring updates cover N-trans-caffeoyltyramine, or NCT, NCTx commercialization activity, pilot-scale production and technology-transfer work, partner validation, strategic focus on pharmaceutical and nutraceutical markets, accelerator participation, investor presentations, and periodic operating results communications.
MDB Capital Holdings (NASDAQ: MDBH) reported operational highlights for the first six months of 2026, including serving as sole bookrunner and underwriter on the $20 million BUDA Juice IPO, joint bookrunner on the $15 million Ticketplus IPO, and completing a $5.9 million public offering for eXoZymes (NASDAQ: EXOZ).
MDB expanded its pipeline of early-stage disruptive companies, advanced discussions with potential MDB Direct/Public Ventures strategic partners, and prepared a spin-out of PatentVest as an independent public company. For the first half of 2026, MDB reported a net loss of approximately $16.1 million, fixed operating expenses of about $5 million, net cash used of about $3 million, and roughly $12.1 million in cash, current assets and marketable securities net of liabilities. Management will host a Zoom webinar on August 13, 2026, at 4:30 p.m. ET.
eXoZymes (NASDAQ:EXOZ) will host a live webinar and conference call on Thursday, August 20, 2026, at 5:00 PM Eastern Time to discuss its second quarter 2026 results. A detailed press release on the quarter will be issued before the call.
CEO Michael Heltzen and select members of the management team will review recent developments, ongoing initiatives and anticipated milestones, followed by a Q&A session. Investors can pre-register for the webinar or access the live event via eXoZymes’ investor relations website.
eXoZymes (NASDAQ: EXOZ) has been selected for the inaugural U.S. Department of Energy Genesis Mission, a nine-month AI initiative uniting national labs, academia and industry. The project totals approximately $747,000 in funding, including about $147,000 awarded to eXoZymes.
eXoZymes will collaborate with Lawrence Berkeley National Laboratory researchers Dr. Edward Baidoo and Dr. Hector Garcia Martin to build AI-powered digital twins for cell-free biomanufacturing. The company will generate curated cell-free enzymatic datasets, while LBNL teams develop metabolomic workflows and hybrid digital twin models that merge enzyme kinetics, reactor physics and machine learning. According to eXoZymes, participation also provides access to the DOE Genesis Mission Platform’s advanced AI models, AI agents and high-performance computing resources.
eXoZymes (NASDAQ:EXOZ) received a $2,028,518 NIH Phase IIB SBIR grant from NIGMS to advance rare cannabinoids and cannabinoid analogs for drug discovery. The two-year, non-dilutive award begins July 1, 2026 and adds a second biosolution to its pipeline alongside NCT.
The program targets advanced enzyme expression systems, expanded analog libraries, and preclinical evaluation of eXoZymes' cannabinoid library. Including this award, total non-dilutive funding to the company and predecessor programs reaches $19.7 million, and includes a sub-award to Dr. Vikram Shende's laboratory at Occidental College.
eXoZymes (NASDAQ:EXOZ) closed a public offering of 330,575 units, including 34,440 from partial over-allotment exercise. Each unit includes two common shares and one warrant. The offering priced shares at $8.99 and warrants at $0.02, for gross proceeds of about $5.95 million.
Warrants become exercisable in one year at $11.24 per share, last five years, and are unlisted. According to eXoZymes, net proceeds will fund NCT development, additional products, R&D, working capital, and general corporate purposes.
eXoZymes (NASDAQ:EXOZ) priced a public offering of units at $18.00 per unit, each containing two common shares and one warrant. The company sold 592,270 shares and 296,135 warrants, for expected gross proceeds of about $5.33 million before expenses.
The underwriter has a 45-day option for up to 44,420 additional units. Warrants have a $11.24 exercise price, a five-year term, reset and redemption features, and will not be listed. Proceeds will support NCT-related development, R&D, and general corporate purposes.
eXoZymes (NASDAQ:EXOZ) announced graduation from the Shell GameChanger Accelerator powered by NLR on May 7, 2026. From 2023–2026 the partnership supported advancement of eXoZymes' cell-free biomanufacturing platform toward commercial viability through technical guidance, separations evaluation, and technoeconomic and lifecycle analysis.
eXoZymes (NASDAQ:EXOZ) CCO Damien Perriman detailed the commercial path for cell-free biomanufacturing and the company’s first spinout, NCTx, on the Grow Everything podcast on April 10, 2026. Perriman said NCTx targets a supplement pathway for NCT while evaluating pharmaceutical options.
The episode highlighted third-party validation: a 100-fold tech transfer with ~99% conversion and 99.6% purity of NCT, which Perriman described as proof of the cell-free platform’s scale-up and tech-transfer capability.
eXoZymes (NASDAQ:EXOZ) provided a fiscal 2025 update on March 31, 2026, reporting increased operating investment, platform validation, and financing preparations.
Key figures: Operating expenses $9.72M, Net loss $9.16M, and Cash $3.04M as of December 31, 2025. The company advanced pilot-scale cell-free biomanufacturing and filed an S-3 in January 2026 ahead of an imminent financing round.
eXoZymes (NASDAQ:EXOZ) will host a webinar on Tuesday, March 31, 2026 at 5:30 PM ET to review fourth quarter and full year 2025 results. CEO Michael Heltzen and select management will discuss recent developments, ongoing initiatives, anticipated milestones, and hold a Q&A.
A press release with results will be issued prior to the call. Investors can pre-register and access the live webinar via the company’s investor relations site at https://exozymes.com/investor.